Report cover image

Global Neuroendocrine Tumors (NETs) Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 183 Pages
SKU # APRC20553225

Description

Summary

According to APO Research, The global Neuroendocrine Tumors (NETs) Treatment market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Neuroendocrine Tumors (NETs) Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Neuroendocrine Tumors (NETs) Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Neuroendocrine Tumors (NETs) Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Neuroendocrine Tumors (NETs) Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Neuroendocrine Tumors (NETs) Treatment include Novartis AG, Pfizer, Inc, Progenics Pharmaceuticals, IpsenPharma, Hutchison MediPharma Limited, Boehringer Ingelheim International, AVEO Oncology and Advanced Accelerator Applications, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Neuroendocrine Tumors (NETs) Treatment, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Neuroendocrine Tumors (NETs) Treatment, also provides the sales of main regions and countries. Of the upcoming market potential for Neuroendocrine Tumors (NETs) Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Neuroendocrine Tumors (NETs) Treatment sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Neuroendocrine Tumors (NETs) Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Neuroendocrine Tumors (NETs) Treatment sales, projected growth trends, production technology, application and end-user industry.

Neuroendocrine Tumors (NETs) Treatment Segment by Company

Novartis AG
Pfizer, Inc
Progenics Pharmaceuticals
IpsenPharma
Hutchison MediPharma Limited
Boehringer Ingelheim International
AVEO Oncology
Advanced Accelerator Applications
Neuroendocrine Tumors (NETs) Treatment Segment by Type

Somatostatin Analogs (SSAs)
Targeted Therapy
Other
Neuroendocrine Tumors (NETs) Treatment Segment by Application

Hospitals
Clinics
Other
Neuroendocrine Tumors (NETs) Treatment Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuroendocrine Tumors (NETs) Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neuroendocrine Tumors (NETs) Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuroendocrine Tumors (NETs) Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Neuroendocrine Tumors (NETs) Treatment market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neuroendocrine Tumors (NETs) Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Neuroendocrine Tumors (NETs) Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Neuroendocrine Tumors (NETs) Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

183 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Neuroendocrine Tumors (NETs) Treatment Market Size, 2020 VS 2024 VS 2031
1.3 Global Neuroendocrine Tumors (NETs) Treatment Market Size Estimates and Forecasts (2020-2031)
1.4 Global Neuroendocrine Tumors (NETs) Treatment Sales Estimates and Forecasts (2020-2031)
1.5 Global Neuroendocrine Tumors (NETs) Treatment Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Neuroendocrine Tumors (NETs) Treatment Market Dynamics
2.1 Neuroendocrine Tumors (NETs) Treatment Industry Trends
2.2 Neuroendocrine Tumors (NETs) Treatment Industry Drivers
2.3 Neuroendocrine Tumors (NETs) Treatment Industry Opportunities and Challenges
2.4 Neuroendocrine Tumors (NETs) Treatment Industry Restraints
3 Neuroendocrine Tumors (NETs) Treatment Market by Manufacturers
3.1 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Manufacturers (2020-2025)
3.2 Global Neuroendocrine Tumors (NETs) Treatment Sales by Manufacturers (2020-2025)
3.3 Global Neuroendocrine Tumors (NETs) Treatment Average Sales Price by Manufacturers (2020-2025)
3.4 Global Neuroendocrine Tumors (NETs) Treatment Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Neuroendocrine Tumors (NETs) Treatment Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Neuroendocrine Tumors (NETs) Treatment Manufacturers, Product Type & Application
3.7 Global Neuroendocrine Tumors (NETs) Treatment Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Neuroendocrine Tumors (NETs) Treatment Market CR5 and HHI
3.8.2 Global Top 5 and 10 Neuroendocrine Tumors (NETs) Treatment Players Market Share by Revenue in 2024
3.8.3 2024 Neuroendocrine Tumors (NETs) Treatment Tier 1, Tier 2, and Tier 3
4 Neuroendocrine Tumors (NETs) Treatment Market by Type
4.1 Neuroendocrine Tumors (NETs) Treatment Type Introduction
4.1.1 Somatostatin Analogs (SSAs)
4.1.2 Targeted Therapy
4.1.3 Other
4.2 Global Neuroendocrine Tumors (NETs) Treatment Sales by Type
4.2.1 Global Neuroendocrine Tumors (NETs) Treatment Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Neuroendocrine Tumors (NETs) Treatment Sales by Type (2020-2031)
4.2.3 Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Type (2020-2031)
4.3 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Type
4.3.1 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Type (2020-2031)
4.3.3 Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Type (2020-2031)
5 Neuroendocrine Tumors (NETs) Treatment Market by Application
5.1 Neuroendocrine Tumors (NETs) Treatment Application Introduction
5.1.1 Hospitals
5.1.2 Clinics
5.1.3 Other
5.2 Global Neuroendocrine Tumors (NETs) Treatment Sales by Application
5.2.1 Global Neuroendocrine Tumors (NETs) Treatment Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Neuroendocrine Tumors (NETs) Treatment Sales by Application (2020-2031)
5.2.3 Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Application (2020-2031)
5.3 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Application
5.3.1 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Application (2020-2031)
5.3.3 Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Application (2020-2031)
6 Global Neuroendocrine Tumors (NETs) Treatment Sales by Region
6.1 Global Neuroendocrine Tumors (NETs) Treatment Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Neuroendocrine Tumors (NETs) Treatment Sales by Region (2020-2031)
6.2.1 Global Neuroendocrine Tumors (NETs) Treatment Sales by Region (2020-2025)
6.2.2 Global Neuroendocrine Tumors (NETs) Treatment Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Neuroendocrine Tumors (NETs) Treatment Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Neuroendocrine Tumors (NETs) Treatment Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Neuroendocrine Tumors (NETs) Treatment Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Neuroendocrine Tumors (NETs) Treatment Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Neuroendocrine Tumors (NETs) Treatment Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Neuroendocrine Tumors (NETs) Treatment Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Region
7.1 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Region
7.1.1 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Region (2020-2025)
7.1.3 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Region (2026-2031)
7.1.4 Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Neuroendocrine Tumors (NETs) Treatment Revenue (2020-2031)
7.2.2 North America Neuroendocrine Tumors (NETs) Treatment Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Neuroendocrine Tumors (NETs) Treatment Revenue (2020-2031)
7.3.2 Europe Neuroendocrine Tumors (NETs) Treatment Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Neuroendocrine Tumors (NETs) Treatment Revenue (2020-2031)
7.4.2 Asia-Pacific Neuroendocrine Tumors (NETs) Treatment Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Novartis AG
8.1.1 Novartis AG Comapny Information
8.1.2 Novartis AG Business Overview
8.1.3 Novartis AG Neuroendocrine Tumors (NETs) Treatment Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Novartis AG Neuroendocrine Tumors (NETs) Treatment Product Portfolio
8.1.5 Novartis AG Recent Developments
8.2 Pfizer, Inc
8.2.1 Pfizer, Inc Comapny Information
8.2.2 Pfizer, Inc Business Overview
8.2.3 Pfizer, Inc Neuroendocrine Tumors (NETs) Treatment Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Pfizer, Inc Neuroendocrine Tumors (NETs) Treatment Product Portfolio
8.2.5 Pfizer, Inc Recent Developments
8.3 Progenics Pharmaceuticals
8.3.1 Progenics Pharmaceuticals Comapny Information
8.3.2 Progenics Pharmaceuticals Business Overview
8.3.3 Progenics Pharmaceuticals Neuroendocrine Tumors (NETs) Treatment Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Progenics Pharmaceuticals Neuroendocrine Tumors (NETs) Treatment Product Portfolio
8.3.5 Progenics Pharmaceuticals Recent Developments
8.4 IpsenPharma
8.4.1 IpsenPharma Comapny Information
8.4.2 IpsenPharma Business Overview
8.4.3 IpsenPharma Neuroendocrine Tumors (NETs) Treatment Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 IpsenPharma Neuroendocrine Tumors (NETs) Treatment Product Portfolio
8.4.5 IpsenPharma Recent Developments
8.5 Hutchison MediPharma Limited
8.5.1 Hutchison MediPharma Limited Comapny Information
8.5.2 Hutchison MediPharma Limited Business Overview
8.5.3 Hutchison MediPharma Limited Neuroendocrine Tumors (NETs) Treatment Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Hutchison MediPharma Limited Neuroendocrine Tumors (NETs) Treatment Product Portfolio
8.5.5 Hutchison MediPharma Limited Recent Developments
8.6 Boehringer Ingelheim International
8.6.1 Boehringer Ingelheim International Comapny Information
8.6.2 Boehringer Ingelheim International Business Overview
8.6.3 Boehringer Ingelheim International Neuroendocrine Tumors (NETs) Treatment Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Boehringer Ingelheim International Neuroendocrine Tumors (NETs) Treatment Product Portfolio
8.6.5 Boehringer Ingelheim International Recent Developments
8.7 AVEO Oncology
8.7.1 AVEO Oncology Comapny Information
8.7.2 AVEO Oncology Business Overview
8.7.3 AVEO Oncology Neuroendocrine Tumors (NETs) Treatment Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 AVEO Oncology Neuroendocrine Tumors (NETs) Treatment Product Portfolio
8.7.5 AVEO Oncology Recent Developments
8.8 Advanced Accelerator Applications
8.8.1 Advanced Accelerator Applications Comapny Information
8.8.2 Advanced Accelerator Applications Business Overview
8.8.3 Advanced Accelerator Applications Neuroendocrine Tumors (NETs) Treatment Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Advanced Accelerator Applications Neuroendocrine Tumors (NETs) Treatment Product Portfolio
8.8.5 Advanced Accelerator Applications Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Neuroendocrine Tumors (NETs) Treatment Value Chain Analysis
9.1.1 Neuroendocrine Tumors (NETs) Treatment Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Neuroendocrine Tumors (NETs) Treatment Production Mode & Process
9.2 Neuroendocrine Tumors (NETs) Treatment Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Neuroendocrine Tumors (NETs) Treatment Distributors
9.2.3 Neuroendocrine Tumors (NETs) Treatment Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.